GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Beneish M-Score

Vascular Biogenics (Vascular Biogenics) Beneish M-Score : -3.01 (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vascular Biogenics's Beneish M-Score or its related term are showing as below:

VBLT' s Beneish M-Score Range Over the Past 10 Years
Min: -7.86   Med: -3.4   Max: 7.9
Current: -3.01

During the past 11 years, the highest Beneish M-Score of Vascular Biogenics was 7.90. The lowest was -7.86. And the median was -3.40.


Vascular Biogenics Beneish M-Score Historical Data

The historical data trend for Vascular Biogenics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Beneish M-Score Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.99 7.90 -2.55 -2.47 -3.89

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.40 -3.68 -3.89 -3.29 -3.01

Competitive Comparison of Vascular Biogenics's Beneish M-Score

For the Biotechnology subindustry, Vascular Biogenics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Beneish M-Score falls into.



Vascular Biogenics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vascular Biogenics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 0.5383+0.404 * 0.2057+0.892 * 0.8409+0.115 * 0.1343
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2055+4.679 * 0.063418-0.327 * 0.9558
=-3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0.481 = $0.48 Mil.
Gross Profit was 0 + -0.002 + 0.048 + 0.418 = $0.46 Mil.
Total Current Assets was $24.55 Mil.
Total Assets was $24.65 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.36 Mil.
Selling, General, & Admin. Expense(SGA) was $10.78 Mil.
Total Current Liabilities was $5.30 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -0.874 + -2.639 + -3.272 + -9.17 = $-15.96 Mil.
Non Operating Income was -0.536 + 0.61 + 0 + 0 = $0.07 Mil.
Cash Flow from Operations was -2.362 + -1.688 + -6.721 + -6.821 = $-17.59 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.064 + 0.113 + 0.196 + 0.199 = $0.57 Mil.
Gross Profit was 0.03 + 0.058 + 0.101 + 0.108 = $0.30 Mil.
Total Current Assets was $35.69 Mil.
Total Assets was $45.32 Mil.
Property, Plant and Equipment(Net PPE) was $8.76 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.36 Mil.
Selling, General, & Admin. Expense(SGA) was $10.64 Mil.
Total Current Liabilities was $8.81 Mil.
Long-Term Debt & Capital Lease Obligation was $1.39 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.481) / (0 / 0.572)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.297 / 0.572) / (0.464 / 0.481)
=0.519231 / 0.964657
=0.5383

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (24.548 + 0) / 24.646) / (1 - (35.688 + 8.755) / 45.319)
=0.003976 / 0.01933
=0.2057

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.481 / 0.572
=0.8409

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.358 / (1.358 + 8.755)) / (0.357 / (0.357 + 0))
=0.134283 / 1
=0.1343

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.781 / 0.481) / (10.635 / 0.572)
=22.413721 / 18.592657
=1.2055

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 5.301) / 24.646) / ((1.389 + 8.809) / 45.319)
=0.215086 / 0.225027
=0.9558

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.955 - 0.074 - -17.592) / 24.646
=0.063418

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vascular Biogenics has a M-score of -3.01 suggests that the company is unlikely to be a manipulator.


Vascular Biogenics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142